NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 1.47 against a street estimate of 2.00 — a miss of 26.5%.
with an average price target of ₹322.25.
| Document | Date |
|---|---|
| Q1 FY27 earnings call VIYASH SCIENTIFIC LIMITED – Q1 FY'27 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue from operations: Rs. 946 crores, up 19.5% year-on-year and 2.9% seq | 2026-08-16 |
| Investor presentation · Q1 FY27 VIYASH SCIENTIFIC LIMITED – Q1 FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Revenue: ₹9,464 Million in Q1 FY27, up 19.5% year-on-year from ₹7,916 Millio | 2026-08-12 |
| Quarterly results · Q1 FY27 VIYASH SCIENTIFIC LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Q1 FY2026-27 (Quarter ended 30 June 2026) Standalone Results: - Revenue from opera | 2026-08-11 |
| Annual report FY2026 VIYASH SCIENTIFIC LIMITED – ANNUAL REPORT FY 2025-26 SUMMARY HEADLINE NUMBERS • Revenue from operations: ₹34,203 million – up 13.8% year-on-year • E | 2026-07-17 |
| Investor presentation · Q4 FY26 VIYASH SCIENTIFIC LIMITED – INVESTOR DAY SUMMARY (JUNE 2026) HEADLINE NUMBERS • FY26 Revenue: INR 34,203 Million (up from INR 30,068 Million in FY25 | 2026-06-25 |
| Q4 FY26 earnings call VIYASH SCIENTIFIC LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • Total Revenue FY26: INR 3,420 crores (13.8% YoY growth vs INR 3,007 crores FY25) • Q4 | 2026-05-22 |
| Quarterly results · Q4 FY26 VIYASH SCIENTIFIC LIMITED – FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue from Operations (FY 2025-26): ₹13,820.60 million (up f | 2026-05-19 |
| Investor presentation | 2026-05-19 |
Readable in the app.
| Announcement | Date |
|---|---|
| Update on proposed acquisition of BioForLife Italia S.r.l Viyash Scientific Limited announced progress on its acquisition of BioForLife Italia S.r.l., an Italian biotech company. The company's Irish subsidiary, Alivira Animal Health Limited, is acq | 2026-09-08 |
| Acquisition of another business completed Viyash Scientific Limited has informed the Exchange about General Updates-Acquisition | 2026-06-08 |
| Credit rating withdrawn following amalgamation scheme completion Symed Labs Ltd has undergone an amalgamation (merger) with another company. As a result of this corporate restructuring, the credit rating agency CRISIL has withdrawn all credit ratings it h | 2026-01-17 |
| Record date set for merger transaction Sequent Scientific Limited has informed the Exchange that Record date for the purpose of Merger is 08-Dec-2025. | 2025-11-26 |
| Update on merger scheme arrangement between entities Update on merger scheme | 2025-11-22 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Viyash Scientific Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.